Skip to main content
. Author manuscript; available in PMC: 2014 Mar 14.
Published in final edited form as: Exp Biol Med (Maywood). 2012 Aug 2;237(7):832–844. doi: 10.1258/ebm.2012.012028

Figure 3. Effect of SKIs on endocrine resistant MDA-MB-468 breast cancer.

Figure 3

(A) Cells were plated at 7.5 × 105 cells per 96 well plate. The following day cells were treated with indicated concentrations of SKI-II (solid line) or ABC294649 (dotted line) for 24 h. Data are presented as percent of vehicle treated samples. Mean values of ± S.E.M. of five different experiments in quadruplicate are reported. (B) Cells were plated at 500 cells per 60 mm2. The following day, cells were treated with SKI-II (solid line) or ABC294649 (dotted line) for 10–14 days. Data are presented as percent of vehicle treated samples. Mean values of ± S.E.M. of three different experiments in duplicate are reported. (C) Cells plated at 10,000 cells per well in a 96 well plate and treated with 50µM of ABC294640 for 24h. Following treatment, cells were measured for defragmented oligonucleotides as a measure of apoptosis using ELISA analyses and (D) cells were analyzed for viability using MTT analyses. Mean values of ± S.E.M. of three different experiments in duplicate are reported.